Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...
Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...
Shares of Hims & Hers Health ( HIMS -24.30%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...
The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.
Hims’s acquisition of Trybe Labs will put it in competition with health industry juggernauts such as Labcorp and Quest ...
Hims & Hers Health, Inc. (NYSE:HIMS) announced the acquisition of a California-based peptide facility to enhance its domestic ...
Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...
Hims & Hers Health Inc (NYSE:HIMS) shares are soaring Wednesday after the company announced plans to introduce at-home lab ...
Hims & Hers Health, Inc. stock surged 1,000% with strategic growth, but high valuation & short interest suggest taking ...
Hims & Hers Health (NYSE:HIMS – Get Free Report) is projected to announce its earnings results after the market closes on ...
Shares of Hims & Hers (NYSE: HIMS) stock are up nearly 500% in the past year, but is the stock in bubble territory, or is there still growth ahead? Travis Hoium tackles that question plus the ...
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results